News summaryThe Motley FoolOct 31, 2026, 02:17 PM
Is AbbVie a Buy After Its Latest Earnings Report?
AbbVie reported third-quarter revenue of $17.4 billion, up 10.3% year over year. [[fact:fact-4g73h93fn]] Adjusted EPS was $3.82, about $0.07 above the midpoint of management's guidance. [[fact:fact-2a9oqr3ez]] Skyrizi revenue rose 22.7% to $5.78 billion, while Rinvoq sales increased 23.9% to $2.71 billion. [[fact:fact-as9cjftcd]] Humira revenue fell to $683 million from $993 million a year earlier. [[fact:fact-dmqkmf8fl]] AbbVie announced a 5.2% dividend increase, raising its quarterly payout from $1.73 to $1.82 per share beginning in February. [[fact:fact-e2vryzzzg]]